# Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI

> **NCT07658105** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** eparlitozoviril
- **OTHER:** Control group

## Key facts

- **NCT ID:** NCT07658105
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-12
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658105, "Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*